SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day.
Collaboration includes strategic investment by CharacterStrong’s parent company FullBloom to further scale K-12 mental health solutions that improve student outcomes
Collaboration includes strategic investment by CharacterStrong’s parent company FullBloom to further scale K-12 mental health solutions that improve student outcomes
LOS ANGELES, July 23, 2025 /PRNewswire/ -- Viewers of Public Television are in for an enlightening experience as "Empowered with Meg Ryan" presents a...
ROTTERDAM, Netherlands, July 23, 2025 /PRNewswire/ -- In a groundbreaking development for the global marine fuels industry, leading shipping and bunkering companies have come...
Global ingredient supplier Corbion has once again demonstrated its strong commitment to sustainability, earning high marks in climate, water, and supplier engagement in CDP’s Disclosure Cycle 2024.
KOLKATA, India, July 23, 2025 /PRNewswire/ -- Himadri Speciality Chemical Ltd, a global frontrunner in advanced materials and sustainable chemical solutions, has been named...
Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services
MCLEAN, Va., July 22,...
HUNTSVILLE, ON, July 21, 2025 /CNW/ - Today, Métis National Council (MNC) President Victoria Pruden met with Premiers and other Regional and National Indigenous Leaders...
SAN FRANCISCO, July 21, 2025 (GLOBE NEWSWIRE) -- Healthcare giant Centene Corporation (NYSE: CNC), a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934.
Grand prize winners each take home $25,000 in prizes
CHANHASSEN, Minn., July 21, 2025 /PRNewswire/ -- Life Time (NYSE: LTH), the nation's premier healthy lifestyle...